...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: Potential interest of target domains to discriminate thrombotic and non-thrombotic patients
【24h】

Contribution of anti-β2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: Potential interest of target domains to discriminate thrombotic and non-thrombotic patients

机译：抗β2糖蛋白I IgA抗体对抗磷脂综合征的诊断的贡献：目标域对区分血栓形成和非血栓形成患者的潜在兴趣

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives: Although the last international guidelines for aPL recommended determination of IgA aCL and anti-β2glycoprotein I (aβ2GPI) antibodies for the evaluation of APS in the absence of conventional IgG or IgM aCL and aβ2GPI antibodies, the clinical value of these antibodies remains controversial. We evaluated the clinical utility of IgA aPL and of the determination of target domains of aβ2GPI IgA antibodies. Methods: A retrospective analysis was performed on sera from 439 patients referred for routine detection of aPL IgA by in-house ELISA. Sera positive for aβ2GPI IgA were subsequently tested for aβ2GPI domain 1 (D1) and domain 4/5 (D4/5) antibodies using ELISAs. Results: The prevalence of aβ2GPI IgA antibodies was 16% in patients, significantly different from controls (1%, P0.0001). These antibodies were associated with clinical contexts related to APS as thrombosis (28.6% vs 15%, P = 0.009) and SLE (42% vs 15%, P0.0001). Interestingly, determination of their target domains revealed a significant association between aβ2GPI IgA directed against D4/5 and SLE without thrombosis (66.7 vs 16.7%, P = 0.002). In contrast, aCL IgA were not more prevalent in patients than in controls. Conclusion: Our study confirmed the interest of aβ2GP1 IgA in the exploration of APS and suggests that identification of target domains of aβ2GP1 IgA may be useful in the evaluation of thrombotic risk in SLE patients.
机译：目的：尽管最新的aPL国际指南建议在不存在常规IgG或IgM aCL和aβ2GPI抗体的情况下确定IgA aCL和抗β2糖蛋白I（aβ2GPI）抗体以评估APS，但这些抗体的临床价值仍有争议。我们评估了IgA aPL的临床效用和aβ2GPIIgA抗体靶域的确定。方法：对439例通过内部ELISA常规检测aPL IgA的患者的血清进行回顾性分析。随后使用ELISA对aβ2GPIIgA阳性的血清测试aβ2GPI域1（D1）和域4/5（D4 / 5）抗体。结果：患者中aβ2GPIIgA抗体的患病率为16％，与对照组相比有显着差异（1％，P <0.0001）。这些抗体与血栓形成（28.6％vs 15％，P = 0.009）和SLE（42％vs 15％，P <0.0001）与APS相关的临床情况相关。有趣的是，确定其靶结构域显示针对D4 / 5的aβ2GPIIgA与无血栓形成的SLE之间存在显着关联（66.7对16.7％，P = 0.002）。相反，aCL IgA在患者中没有比在对照组中更普遍。结论：我们的研究证实了aβ2GP1IgA在探索APS中的兴趣，并建议鉴定aβ2GP1IgA的靶域可能有助于评估SLE患者的血栓形成风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号